NYSE : BIO.B
Bio-Rad Laboratories, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 379.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.99B |
| Enterprise Value | 9.74B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 5.06M |
| Shares Outstanding | 26.74M |
| Shares Change (YoY) | -3.11% |
| Shares Change (QoQ) | -0.53% |
| Owned by Insiders (%) | 4.79% |
| Owned by Institutions (%) | 72.88% |
| Float | 21.35M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 45.97 |
| Forward PE | 40.99 |
| PS Ratio | 3.86 |
| Forward PS | 3.80 |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.55 |
| P/FCF Ratio | 28.29 |
| P/OCF Ratio | 20.28 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 43.80 |
| EV / Sales | 3.76 |
| EV / EBITDA | 22.09 |
| EV / EBIT | 35.77 |
| EV / FCF | 27.59 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.14 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 3.88 |
| Interest Coverage | 5.58 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 3.11% |
| Return on Assets (ROA) | 1.66% |
| Return on Invested Capital (ROIC) | 2.54% |
| Return on Capital Employed (ROCE) | 2.93% |
| Weighted Average Cost of Capital (WACC) | 9.18% |
| Revenue Per Employee | $347,557 |
| Profits Per Employee | $29,852 |
| Employee Count | 7,450 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 1.57 |
Taxes
| Measure | Value |
|---|
| Income Tax | 128.00M |
| Effective Tax Rate | 36.53% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +18.18% |
| 50-Day Moving Average | 295.40 |
| 200-Day Moving Average | 465.74 |
| Relative Strength Index (RSI) | 71.85 |
| Average Volume (20 Days) | 401 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1 |
| Short Previous Month | 2 |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.00 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.59B |
| Gross Profit | 1.35B |
| Operating Income | 272.30M |
| Pretax Income | 350.40M |
| Net Income | 222.40M |
| EBITDA | 441.00M |
| EBIT | 272.30M |
| Earnings Per Share (EPS) | $8.26 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.62B |
| Total Debt | 1.37B |
| Net Cash | 248.10M |
| Net Cash Per Share | $9.28 |
| Equity (Book Value) | 7.17B |
| Book Value Per Share | 268.30 |
| Working Capital | 2.06B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 492.60M |
| Capital Expenditures | -139.50M |
| Depreciation & Amortization | 168.70M |
| Net Borrowing | -500,000 |
| Free Cash Flow | 353.10M |
| FCF Per Share | $13.21 |
Margins
| Measure | Value |
|---|
| Gross Margin | 52.04% |
| Operating Margin | 10.52% |
| Pretax Margin | 13.53% |
| Profit Margin | 8.59% |
| EBITDA Margin | 17.03% |
| EBIT Margin | 10.52% |
| FCF Margin | 13.64% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 3.11% |
| Shareholder Yield | 3.11% |
| Earnings Yield | 2.18% |
| FCF Yield | 3.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 0.91% |
| EPS Growth Forecast (3Y) | -0.37% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.19 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |